Earlier in the summer, Children’s Tumor Foundation President Annette Bakker, PhD and Richard Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec had a conversation about the Foundation, the patient journey, and future prospects for those living with NF. A summary of their conversation was published on the WuXi AppTec website.
In it, Annette discusses ongoing clinical trials and the impact CTF has had on available trials through our early seed funding. Richard and Annette also discussed the vital importance of open data, and the multiple ways the Children’s Tumor Foundation is evolving scientific research with platforms and collaborations intended to speed up the drug discovery process.
“We play a pretty unique role in the R&D ecosystem supporting disruptive technology, discovery and preclinical development to clinic,” emphasized Bakker, “our organization is here to not just to fund new discoveries, but to empower the critical work that guarantees that awesome discoveries are turned more quickly into effective treatments. We like good publications, sure, but we like even more to see patients that are not suffering from NF anymore.”
Click here to read the full article.
Richard Soll joined the Children’s Tumor Foundation Board of Directors in 2018.
